Form 4: Castle Biosciences Executive Trades Shares and Restricted Stock Units
SEC Form 4 Filing
A Castle Biosciences executive, Juvenal Tobin, engaged in multiple transactions involving common stock and restricted stock units, including both acquisitions and disposals.
Summary
- Juvenal Tobin, Chief Commercial Officer at Castle Biosciences, executed several transactions involving the company's common stock.
- These transactions included the acquisition of common stock through the vesting of restricted stock units (RSUs) and the sale of common stock.
- On December 9, 2024, 15,961 RSUs vested and were converted to common stock, and 3,887 shares were sold at $30.91 per share.
- On December 10, 2024, 1,750 RSUs vested and were converted to common stock, and 495 shares were sold at $29.63 per share.
- Also on December 10, 2024, 6,169 RSUs vested and were converted to common stock, and 1,503 shares were sold at $29.63 per share.
- The transactions were conducted by Juvenal Tobin and the Susan M Juvenal Family Revocable Trust, of which he and his spouse are trustees and beneficiaries.
- The RSUs were granted on December 9, 2022, December 10, 2020, and December 10, 2021, and vest in four equal installments.
Sentiment
Score: 5
Explanation: The document reflects routine executive stock transactions, which are neither particularly positive nor negative. The transactions are part of the executive's compensation and vesting schedule.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies, often tied to compensation packages and vesting schedules. These transactions are closely monitored by investors for insights into management's perspective on the company's future.
Comparison to Industry Standards
- Executive stock transactions are a standard part of compensation for publicly traded companies.
- The vesting schedules of the RSUs are typical, with four equal installments over a period of time.
- The sale of shares after vesting is also a common practice for executives to realize the value of their equity compensation.
- Comparable companies in the biotech sector also have similar executive compensation structures involving RSUs and stock options.
Related Party Transactions
- The transactions were conducted by Juvenal Tobin and the Susan M Juvenal Family Revocable Trust, of which he and his spouse are trustees and beneficiaries.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they involve a relatively small number of shares compared to the total outstanding shares.
- The transactions are part of the executive's compensation and do not indicate any significant change in the company's performance or outlook.
Key Dates
| Date | Description |
|---|---|
| 2020-12-10 | Grant date of 7,000 RSUs which vest in four equal installments beginning on December 10, 2021. |
| 2021-12-10 | Grant date of 24,679 RSUs which vest in four equal installments beginning on December 10, 2022. |
| 2022-12-09 | Grant date of 63,844 RSUs which vest in four equal installments beginning on December 9, 2023. |
| 2024-12-09 | 15,961 RSUs vested and 3,887 shares were sold. |
| 2024-12-10 | 1,750 RSUs vested and 495 shares were sold, and 6,169 RSUs vested and 1,503 shares were sold. |
| 2024-12-11 | Date of filing. |
Keywords
Castle Biosciences, CSTL, stock transactions, restricted stock units, executive trading, insider trading, share sales, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.